Roche announced new data from the VOYAGER study confirming the real-world effectiveness, durability and safety of Vabysmo, also known as faricimab, in neovascular age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. The results, presented at the EURETINA 2026 Annual Meeting in Vienna, Austria, showed vision gains and anatomical improvements in previously untreated eyes and stable or improved vision with improved anatomical outcomes in previously treated eyes across all study cohorts. In the nAMD and DME cohorts, vision and central subfield thickness improved in previously untreated eyes after 12 months of treatment, while in the central and hemi-RVO cohort both vision and CST improved in untreated and treated eyes after six months. With more than 5,000 patients enrolled across 28 countries and regions, VOYAGER is the largest prospective, non-interventional real-world dataset evaluating Vabysmo, and the study's safety profile was generally consistent with that established in Phase III trials. Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said the sustained visual improvements and meaningful anatomical drying reinforce the role of Vabysmo in addressing unmet needs for patients with retinal conditions. Vabysmo is approved in more than 100 countries for nAMD and DME and in more than 60 countries for macular edema following RVO.
Roche Holding AGVOYAGER real-world data confirm Vabysmo's effectiveness, durability and safety across retinal conditions, supporting the drug's clinical profile.
Rogers Corporation
